TABLE OF CONTENTS
1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET 46
1.4 LIMITATIONS 48
1.5 MARKETS COVERED 48
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 PRODUCT TYPE LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET END USER COVERAGE GRID 60
2.11 VENDOR SHARE ANALYSIS 61
2.12 SECONDARY SOURCES 62
2.13 ASSUMPTIONS 62
3 EXECUTIVE SUMMARY 63
4 PREMIUM INSIGHTS 66
4.1 PESTEL ANALYSIS 67
4.2 PORTERS FIVE FORCES 68
5 INDUSTRY INSIGHTS 69
6 EPIDEMIOLOGY 70
7 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, REGULATIONS 71
7.1 REGULATORY SCENARIO IN THE U.S 71
7.2 REGULATORY SCENARIO IN AUSTRALIA 72
7.3 REGULATORY SCENARIO IN JAPAN 72
7.4 REGULATORY SCENARIO IN CHINA 72
8 MARKET OVERVIEW 74
8.1 DRIVERS 76
8.1.1 GROWING PREVALENCE OF THROAT CANCER 76
8.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN THROAT CANCER DIAGNOSTICS 76
8.1.3 INCREASE IN AWARENESS REGARDING THROAT CANCER 77
8.2 RESTRAINTS 77
8.2.1 LATE DIAGNOSIS AND POOR PROGNOSIS OF THROAT CANCER 77
8.2.2 HIGH COST FOR THE INSTALLATION OF DIAGNOSTIC DEVICES. 77
8.3 OPPORTUNITIES 78
8.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 78
8.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 79
8.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 79
8.4 CHALLENGES 80
8.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 80
8.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 80
9 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 81
9.1 OVERVIEW 82
9.2 INSTRUMENTS 85
9.2.1 PATHOLOGY-BASED INSTRUMENTS 86
9.2.1.1 PCR INSTRUMENTS 86
9.2.1.2 SLIDE STAINING SYSTEMS 86
9.2.1.3 TISSUE PROCESSING SYSTEMS 87
9.2.1.4 CELL PROCESSORS 87
9.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 87
9.2.2 IMAGING INSTRUMENTS 87
9.2.2.1 ULTRASOUND SYSTEMS 87
9.2.2.2 CT SYSTEMS 87
9.2.2.3 MRI SYSTEMS 87
9.2.2.4 OTHERS 88
9.2.3 BIOPSY INSTRUMENTS 88
9.2.4 OTHERS 88
9.3 CONSUMABLES & ACCESSORIES 88
9.3.1 KITS 89
9.3.1.1 PCR KITS 89
9.3.1.2 DNA POLYMERASE KITS 89
9.3.1.3 NUCLEIC ACID ISOLATION KITS 89
9.3.1.4 OTHERS 90
9.3.2 REAGENTS 90
9.3.2.1 ASSAYS 90
9.3.2.2 BUFFERS 90
9.3.2.3 PRIMERS 90
9.3.2.4 OTHERS 90
9.3.3 PROBES 90
9.3.4 OTHER CONSUMABLES 90
10 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY TEST TYPE 91
10.1 OVERVIEW 92
10.2 IMAGING TEST 95
10.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 96
10.2.2 MRI 96
10.2.3 CHEST X-RAY 96
10.2.4 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 96
10.2.5 OTHERS 96
10.3 BLOOD TEST 96
10.3.1 BLOOD CHEMISTRY TESTS 98
10.3.2 COMPLETE BLOOD COUNT (CBC) 98
10.3.3 OTHERS 98
10.4 BIOPSY 98
10.4.1 ENDOSCOPIC BIOPSY 99
10.4.2 FINE NEEDLE ASPIRATION (FNA) BIOPSY 99
10.4.3 OTHERS 99
10.5 OTHERS 100
11 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 101
11.1 OVERVIEW 102
11.2 PHARYNGEAL CANCER 105
11.2.1 NASOPHARYNGEAL CANCER 106
11.2.2 OROPHARYNGEAL CANCER 106
11.2.3 HYPOPHARYNGEAL CANCER 106
11.3 LARYNGEAL CANCER 107
12 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY STAGES 108
12.1 OVERVIEW 109
12.2 STAGE III 112
12.3 STAGE II 112
12.4 STAGE IV 113
12.5 STAGE I 114
12.6 STAGE 0 115
13 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY AGE 116
13.1 OVERVIEW 117
13.2 30-65 120
13.3 65 AND ABOVE 121
13.4 21-29 121
13.5 BELOW 21 122
14 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY END USER 123
14.1 OVERVIEW 124
14.2 HOSPITALS 127
14.3 ASSOCIATED LABS 127
14.4 INDEPENDENT DIAGNOSTIC LABORATORIES 128
14.5 DIAGNOSTIC IMAGING CENTERS 129
14.6 CANCER RESEARCH INSTITUTES 130
14.7 OTHERS 131
15 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 132
15.1 OVERVIEW 133
15.2 DIRECT TENDER 136
15.3 RETAIL SALES 137
16 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, BY REGION 138
16.1 NORTH AMERICA 139
16.1.1 U.S. 149
16.1.2 CANADA 154
16.1.3 MEXICO 159
17 NORTH AMERICA THROAT CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 164
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 164
18 SWOT ANALYSIS 165
19 COMPANY PROFILE 166
19.1 F. HOFFMANN- LA ROCHE LTD 166
19.1.1 COMPANY SNAPSHOT 166
19.1.2 REVENUE ANALYSIS 166
19.1.3 COMPANY SHARE ANALYSIS 167
19.1.4 PRODUCT PORTFOLIO 167
19.1.5 RECENT DEVELOPMENT 167
19.2 FUJIFILM CORPORATION 168
19.2.1 COMPANY SNAPSHOT 168
19.2.2 REVENUE ANALYSIS 168
19.2.3 COMPANY SHARE ANALYSIS 169
19.2.4 PRODUCT PORTFOLIO 169
19.2.5 RECENT DEVELOPMENT 169
19.3 THERMO FISHER SCIENTIFIC INC. 170
19.3.1 COMPANY SNAPSHOT 170
19.3.2 REVENUE ANALYSIS 170
19.3.3 COMPANY SHARE ANALYSIS 171
19.3.4 PRODUCT PORTFOLIO 171
19.3.5 RECENT DEVELOPMENTS 171
19.4 CANON MEDICAL SYSTEMS CORPORATION 172
19.4.1 COMPANY SNAPSHOT 172
19.4.2 REVENUE ANALYSIS 172
19.4.3 COMPANY SHARE ANALYSIS 173
19.4.4 PRODUCT PORTFOLIO 173
19.4.5 RECENT DEVELOPMENT 173
19.5 KONINKLIJKE PHILIPS N.V. 174
19.5.1 COMPANY SNAPSHOT 174
19.5.2 REVENUE ANALYSIS 174
19.5.3 COMPANY SHARE ANALYSIS 175
19.5.4 PRODUCT PORTFOLIO 175
19.5.5 RECENT DEVELOPMENT 176
19.6 ABBOTT 177
19.6.1 COMPANY SNAPSHOT 177
19.6.2 REVENUE ANALYSIS 177
19.6.3 PRODUCT PORTFOLIO 178
19.6.4 RECENT DEVELOPMENTS 178
19.7 AGILENT TECHNOLOGIES, INC. 179
19.7.1 COMPANY SNAPSHOT 179
19.7.2 REVENUE ANALYSIS 179
19.7.3 PRODUCT PORTFOLIO 180
19.7.4 RECENT DEVELOPMENT 180
19.8 BD 181
19.8.1 COMPANY SNAPSHOT 181
19.8.2 REVENUE ANALYSIS 181
19.8.3 PRODUCT PORTFOLIO 182
19.8.4 RECENT DEVELOPMENTS 182
19.9 BEIJING O&D BIOTECH CO., LTD. 183
19.9.1 COMPANY SNAPSHOT 183
19.9.2 PRODUCT PORTFOLIO 183
19.9.3 RECENT DEVELOPMENT 183
19.10 BIO-RAD LABORATORIES, INC. 184
19.10.1 COMPANY SNAPSHOT 184
19.10.2 REVENUE ANALYSIS 184
19.10.3 PRODUCT PORTFOLIO 185
19.10.4 RECENT DEVELOPMENT 185
19.11 FONAR CORP. 186
19.11.1 COMPANY SNAPSHOT 186
19.11.2 REVENUE ANALYSIS 186
19.11.3 PRODUCT PORTFOLIO 187
19.11.4 RECENT DEVELOPMENT 187
19.12 GE HEALTHCARE 188
19.12.1 COMPANY SNAPSHOT 188
19.12.2 REVENUE ANALYSIS 188
19.12.3 PRODUCT PORTFOLIO 189
19.12.4 RECENT DEVELOPMENT 189
19.13 HOLOGIC INC. 190
19.13.1 COMPANY SNAPSHOT 190
19.13.2 REVENUE ANALYSIS 190
19.13.3 PRODUCT PORTFOLIO 191
19.13.4 RECENT DEVELOPMENT 191
19.14 ILLUMINA, INC. 192
19.14.1 COMPANY SNAPSHOT 192
19.14.2 REVENUE ANALYSIS 192
19.14.3 PRODUCT PORTFOLIO 193
19.14.4 RECENT DEVELOPMENT 193
19.15 MEDONICA CO. LTD 194
19.15.1 COMPANY SNAPSHOT 194
19.15.2 PRODUCT PORTFOLIO 194
19.15.3 RECENT DEVELOPMENT 194
19.16 MERCK KGAA 195
19.16.1 COMPANY SNAPSHOT 195
19.16.2 REVENUE ANALYSIS 195
19.16.3 PRODUCT PORTFOLIO 196
19.16.4 RECENT DEVELOPMENT 196
19.17 MINFOUND MEDICAL SYSTEMS CO., LTD 197
19.17.1 COMPANY SNAPSHOT 197
19.17.2 PRODUCT PORTFOLIO 197
19.17.3 RECENT DEVELOPMENT 197
19.18 MYRIAD GENETICS, INC. 198
19.18.1 COMPANY SNAPSHOT 198
19.18.2 REVENUE ANALYSIS 198
19.18.3 PRODUCT PORTFOLIO 199
19.18.4 RECENT DEVELOPMENT 199
19.19 PLEXBIO 200
19.19.1 COMPANY SNAPSHOT 200
19.19.2 PRODUCT PORTFOLIO 200
19.19.3 RECENT DEVELOPMENT 200
19.20 QIAGEN 201
19.20.1 COMPANY SNAPSHOT 201
19.20.2 REVENUE ANALYSIS 201
19.20.3 PRODUCT PORTFOLIO 202
19.20.4 RECENT DEVELOPMENT 202
19.21 QUEST DIAGNOSTICS INCORPORATED 203
19.21.1 COMPANY SNAPSHOT 203
19.21.2 REVENUE ANALYSIS 203
19.21.3 PRODUCT PORTFOLIO 204
19.21.4 RECENT DEVELOPMENT 204
19.22 SIEMENS HEALTHCARE GMBH 205
19.22.1 COMPANY SNAPSHOT 205
19.22.2 REVENUE ANALYSIS 205
19.22.3 PRODUCT PORTFOLIO 206
19.22.4 RECENT DEVELOPMENT 206
19.23 STERNMED GMBH 207
19.23.1 COMPANY SNAPSHOT 207
19.23.2 PRODUCT PORTFOLIO 207
19.23.3 RECENT DEVELOPMENT 207
19.24 TIME MEDICAL HOLDING. 208
19.24.1 COMPANY SNAPSHOT 208
19.24.2 PRODUCT PORTFOLIO 208
19.24.3 RECENT DEVELOPMENT 208
20 QUESTIONNAIRE 209

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.